Massive Dilutive Offering at Deep Discount Amidst Going Concern Doubts

summarizeSummary

Exousia Pro is conducting a highly dilutive Regulation A offering at a deep discount to raise capital, while also disclosing significant going concern doubts and an increase in shares offered by selling shareholders.

check_boxKey Events

• Massive Dilutive Offering

  The company is offering up to 50,000,000 shares of common stock, aiming to raise approximately $1.5 million. This represents an extremely high percentage of the company's current market capitalization.

• Deep Discount Pricing

  Shares are being offered at $0.03 each, a significant discount compared to the current market price of $0.041 per share, indicating a distressed capital raise.

• Increased Selling Shareholder Activity

  Selling shareholders are offering an additional 15,000,000 shares, from which the company will receive no proceeds, further contributing to potential market overhang and dilution.

• Explicit Going Concern Warning

  The filing reiterates substantial doubt about the company's ability to continue as a viable business, underscoring the critical nature of this capital raise.

auto_awesomeAnalysis

Exousia Pro, a micro-cap biotechnology company, has significantly increased its Regulation A offering, seeking to raise up to $1.5 million by issuing 50 million shares at a deep discount of $0.03 per share, compared to its current stock price of $0.041. This offering represents an extreme level of dilution, potentially increasing the total outstanding shares by over 139% from the company's portion alone, and even more with potential Series B Preferred conversions. The company explicitly states substantial doubt about its ability to continue as a going concern, highlighting the critical need for this capital. Furthermore, existing shareholders are offering an additional 15 million shares, from which the company will receive no proceeds, adding to the dilutive overhang and signaling a lack of confidence from some holders. The proceeds are earmarked for critical R&D and working capital, but the terms of the raise underscore the company's precarious financial position and the significant risks for current and prospective investors.